Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00619619 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

A Phase 2 study of Depression and Major Depressive Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target
9
Study locations

NCT00619619 is a Phase 2 study of Depression and Major Depressive Disorder that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 59 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00619619, a Phase 2 study of Depression and Major Depressive Disorder, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target
9
Study locations

Study Summary

The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR in children and adolescents with major depressive disorder.

Conditions Studied

Depression Major Depressive Disorder

Interventions

  • DRUG Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)

Study Locations (9)

Arkansas

  • Pfizer Investigational Site - Little Rock

Florida

  • Pfizer Investigational Site - North Miami

Indiana

  • Pfizer Investigational Site - Terre Haute

Kansas

  • Pfizer Investigational Site - Wichita

Louisiana

  • Pfizer Investigational Site - New Orleans

New York

  • Pfizer Investigational Site - New York

Ohio

  • Pfizer Investigational Site - Cleveland

Pennsylvania

  • Pfizer Investigational Site - Hershey

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2008-02
Est. Completion 2009-11
Phase Phase 2

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00619619

The ClinicalTrials.gov registry entry for NCT00619619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) is the first listed.

NCT00619619 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arkansas, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT00619619 about?

NCT00619619 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder". The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR i...

What is the current status of trial NCT00619619?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2008-02. Estimated completion is 2009-11.

What conditions does trial NCT00619619 study?

This clinical trial studies the following conditions: Depression, Major Depressive Disorder.

What interventions are being tested in trial NCT00619619?

The interventions under investigation include: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) (DRUG).

Who is sponsoring clinical trial NCT00619619?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00619619 being conducted?

This trial has 9 study locations across Arkansas, Florida, Indiana, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depression

All registered trials for this condition

Major Depressive Disorder

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.